Fig. 5

PI3K/AKT pathway activity is required for the induction of Postn by bFGF removal and TGFβ activation. A NeuNDL cells were treated with 25 µM LY294004 or DMSO control in both PBS and 10 ng/ml bFGF supplemented medium in the absence of MEGS for 0.5 and 24 h. pAKT (S473) was used as a control for the inhibition of PI3K. B NeuNDL cells were treated the exact same way as in (A) but with 10 µM of MK-2206 instead of LY294004. C NeuNDL cells were treated with or without 10 ng/ml TGFβ-1 in combination with either 10 µM MK-2206 or DMSO controls. pSMAD2 (S465/467) and pAKT (S473) were used as control for TGFβR activation and AKT inhibition, respectively. D Medium was pretreated with bFGF neutralizing antibody or control IgG in combination with either DMSO or 10 µM MK-2206. pAKT (S473) was used as control for AKT inhibition. In all panel PBS designates MEGS-depleted conditions